BACKGROUND AND PURPOSE: Here we have examined the effects of the novel peptide antagonist N-[1-(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-5-yl]aminocarbonyl]-glycinyl-L-lysinyl-L-phenylalanyl-N-benzhydrylamide (K-14585) on proteinase-activated receptor (PAR)(2)-mediated intracellular signalling events. EXPERIMENTAL APPROACH: Using NCTC2544 cells expressing PAR(2), we assessed the effects of K-14585 on PAR(2)-mediated [(3)H] inositol phosphate accumulation, MAP kinase activation, p65 NFkappaB phosphorylation and DNA binding and IL-8 production. KEY RESULTS: Pretreatment with K-14585 (5 microM) inhibited [(3)H] inositol phosphate levels stimulated by PAR(2)-activating peptide Ser-Leu-Ile-Gly-Lys-Val (SLIGKV-OH) in PAR(2)-expressing NCTC2544 cells. K-14585 pretreatment did not influence PAR(2)-mediated extracellular regulated kinase activation but inhibited p38 MAP kinase phosphorylation. At a higher concentration (30 microM), K-14585 alone stimulated p38 MAP kinase activation. These effects were replicated in EAhy926 cells, endogenously expressing PAR(2), but not in parental or PAR(4)-expressing NCTC2544 cells, suggesting these effects were PAR(2)-dependent. SLIGKV-mediated stimulation of p38 MAP kinase phosphorylation was substantially reduced by the G(q/11) inhibitor YM-254890, without affecting K-14585-mediated phosphorylation. Pretreatment with K-14585 inhibited PAR(2)-mediated p65 NFkappaB phosphorylation and NFkappaB-DNA binding. K-14585 (30 microM) alone stimulated comparable NFkappaB reporter activity to SLIGKV-OH. K-14585 inhibited SLIGKV-stimulated IL-8 production, but given alone increased IL-8. While SLIGKV-induced IL-8 formation was reduced by both SB203580 and YM-254890, the response to K-14585 was sensitive to SB203580 but not YM-254890. CONCLUSIONS AND IMPLICATIONS: These data reveal that K-14585 has a duality of action functioning both as an antagonist and agonist due to either partial agonist actions or possible agonist-directed signalling. The data also suggest two modes of p38 MAP kinase activation emanating from PAR(2), one G(q/11)-dependent and the other G(q/11)-independent.
BACKGROUND AND PURPOSE: Here we have examined the effects of the novel peptide antagonist N-[1-(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-5-yl]aminocarbonyl]-glycinyl-L-lysinyl-L-phenylalanyl-N-benzhydrylamide (K-14585) on proteinase-activated receptor (PAR)(2)-mediated intracellular signalling events. EXPERIMENTAL APPROACH: Using NCTC2544 cells expressing PAR(2), we assessed the effects of K-14585 on PAR(2)-mediated [(3)H] inositol phosphate accumulation, MAP kinase activation, p65NFkappaB phosphorylation and DNA binding and IL-8 production. KEY RESULTS: Pretreatment with K-14585 (5 microM) inhibited [(3)H] inositol phosphate levels stimulated by PAR(2)-activating peptide Ser-Leu-Ile-Gly-Lys-Val (SLIGKV-OH) in PAR(2)-expressing NCTC2544 cells. K-14585 pretreatment did not influence PAR(2)-mediated extracellular regulated kinase activation but inhibited p38 MAP kinase phosphorylation. At a higher concentration (30 microM), K-14585 alone stimulated p38 MAP kinase activation. These effects were replicated in EAhy926 cells, endogenously expressing PAR(2), but not in parental or PAR(4)-expressing NCTC2544 cells, suggesting these effects were PAR(2)-dependent. SLIGKV-mediated stimulation of p38 MAP kinase phosphorylation was substantially reduced by the G(q/11) inhibitor YM-254890, without affecting K-14585-mediated phosphorylation. Pretreatment with K-14585 inhibited PAR(2)-mediated p65NFkappaB phosphorylation and NFkappaB-DNA binding. K-14585 (30 microM) alone stimulated comparable NFkappaB reporter activity to SLIGKV-OH. K-14585 inhibited SLIGKV-stimulated IL-8 production, but given alone increased IL-8. While SLIGKV-induced IL-8 formation was reduced by both SB203580 and YM-254890, the response to K-14585 was sensitive to SB203580 but not YM-254890. CONCLUSIONS AND IMPLICATIONS: These data reveal that K-14585 has a duality of action functioning both as an antagonist and agonist due to either partial agonist actions or possible agonist-directed signalling. The data also suggest two modes of p38 MAP kinase activation emanating from PAR(2), one G(q/11)-dependent and the other G(q/11)-independent.
Authors: N Yoshida; K Katada; O Handa; T Takagi; S Kokura; Y Naito; N Mukaida; T Soma; Y Shimada; T Yoshikawa; T Okanoue Journal: Int J Mol Med Date: 2007-02 Impact factor: 4.101
Authors: Rithwik Ramachandran; Laura R Sadofsky; Yupei Xiao; Andrew Botham; Michael Cowen; Alyn H Morice; Steven J Compton Journal: Am J Physiol Lung Cell Mol Physiol Date: 2006-12-01 Impact factor: 5.464
Authors: Scott R Macfarlane; Callum M Sloss; Pamela Cameron; Toru Kanke; Roderick C McKenzie; Robin Plevin Journal: Br J Pharmacol Date: 2005-06 Impact factor: 8.739
Authors: A Crilly; E Burns; M B Nickdel; J C Lockhart; M E Perry; P W Ferrell; D Baxter; J Dale; L Dunning; H Wilson; J S Nijjar; J A Gracie; W R Ferrell; I B McInnes Journal: Ann Rheum Dis Date: 2012-01-30 Impact factor: 19.103
Authors: Rithwik Ramachandran; Koichiro Mihara; Hyunjae Chung; Bernard Renaux; Chang S Lau; Daniel A Muruve; Kathryn A DeFea; Michel Bouvier; Morley D Hollenberg Journal: J Biol Chem Date: 2011-05-16 Impact factor: 5.157
Authors: Scott Boitano; Justin Hoffman; Andrea N Flynn; Marina N Asiedu; Dipti V Tillu; Zhenyu Zhang; Cara L Sherwood; Candy M Rivas; Kathryn A DeFea; Josef Vagner; Theodore J Price Journal: Br J Pharmacol Date: 2015-08-03 Impact factor: 8.739
Authors: Leila M Sevigny; Ping Zhang; Andrew Bohm; Katherine Lazarides; George Perides; Lidija Covic; Athan Kuliopulos Journal: Proc Natl Acad Sci U S A Date: 2011-05-02 Impact factor: 11.205
Authors: Nguyen Huu Tu; Dane D Jensen; Bethany M Anderson; Elyssa Chen; Nestor N Jimenez-Vargas; Nicole N Scheff; Kenji Inoue; Hung D Tran; John C Dolan; Tamaryn A Meek; Morley D Hollenberg; Cheng Z Liu; Stephen J Vanner; Malvin N Janal; Nigel W Bunnett; Laura E Edgington-Mitchell; Brian L Schmidt Journal: J Neurosci Date: 2020-11-10 Impact factor: 6.167